Rare Diseases

These disease state webinars are sponsored, developed and presented by PRIME.

Sponsored webinar that discussed the importance of biomarker testing for metastatic non-small cell lung cancer.

Sponsored webinar that introduced a new treatment for chronic graft-versus-host disease (cGVHD).

Sponsored webinar that discussed the urgency needed to diagnose lupus nephritis as early as possible, and the multidisciplinary care needed in patient management to prevent irreversible kidney damage and progression to end-stage renal disease (ESRD).

Sponsored webinar that discussed the urgency needed to diagnose lupus nephritis as early as possible, and the multidisciplinary care needed in patient management to prevent irreversible kidney damage and progression to end-stage renal disease (ESRD).

Sponsored webinar that provided insights into the "hidden" burden of Systemic Lupus Erythematosus (SLE): a multisystemic autoimmune disease.

Sponsored webinar that discussed topics such as, the RNAi overview, the disease burden of PH1, PH2 and PH3, and an RNAi technology as a potential treatment approach for this rare condition.

Sponsored webinar that discussed topics such as, the RNAi overview, the disease burden of PH1, PH2 and PH3, and an RNAi technology as a potential treatment approach for this rare condition.

Sponsored webinar that reframed the landscape of Chemotherapy-induced myelosuppression (CIM) with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy.

Sponsored webinar that reframed the landscape of Chemotherapy-induced myelosuppression (CIM) with a fresh perspective on the root of the clinical problem, the patient burden revealed through real world management of CIM, and the hope for a future that fulfills the unmet need – one made more complicated by the confounding influence of Covid-19 in the day-to-day management of people facing malignancy.